ArticleCureus2026
Facial Skin Quality Improvement Using Profhilo®: A Three-Dimensional VECTRA® Image Analysis in a South American Patient.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facial aging is a multifactorial process that involves changes in the skin, soft tissues, musculature, and bone structure, resulting in laxity, loss of contour definition, and alterations in skin texture. This case report describes the treatment of a 57-year-old South American female patient whose primary complaint was facial aging, using the biorestructuring agent Profhilo® (IBSA Farmaceutici Italia Srl, Lodi, Italy) in combination with three-dimensional analysis via VECTRA® 3D (Canfield Scientific, Inc., Parsippany, NJ, USA). The therapeutic protocol consisted of two sessions, spaced four weeks apart, with the product applied at strategic points according to the Bio Aesthetic Points protocol, aiming to stimulate collagen production, promote deep hydration, and restore facial architecture. Pre- and post-treatment evaluation with VECTRA® 3D allowed the objective measurement of wrinkles, pores, texture, skin uniformity, and facial contours. Global improvements in firmness, hydration, texture, and contour definition were observed, demonstrating the bioremodeling and biostimulating effects of Profhilo®, with natural and progressive results. The findings from this case indicate that two sessions of Profhilo® can promote significant skin regeneration and facial rejuvenation, highlighting its applicability in postmenopausal South American populations. Moreover, this report emphasizes the utility of Profhilo® as a minimally invasive alternative for facial rejuvenation and reinforces the role of VECTRA® 3D as an objective and precise tool for the three-dimensional evaluation of aesthetic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.